ELVN
Enliven Therapeutics, Inc.Healthcare · $3.2B market cap
Verdict
We can't put a fair value on ELVN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ELVN
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 30, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about ELVN
Are insiders buying ELVN?
Since Oct 30, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar).
How can I check ELVN's value myself?
Use the free Sticker Price calculator, already filled with ELVN's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 3, 2026. How the Payback Price works